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Abstract: Current management of diabetic macular edema (DME) predominantly involves
treatment with short-acting intravitreal injections of anti-vascular endothelial growth factors
(anti-VEGFs) and/or corticosteroids; however, short-acting therapies (lasting between 1 and
6 months) require frequent injections to maintain efficacy, meaning a considerable treatment
burden for diabetic patients with multiple comorbidities. Continuous injections needed in
some cases are an economic burden for patients/healthcare system, so real-life clinical
practice tends to adopt a reactive approach, ie, watch and wait for worsening symptoms,
which consequently increases the risk of undertreatment and edema recurrence. On
March 7th 2019, a group of experts in retinal medicine and surgery held a roundtable
meeting in Madrid, Spain to discuss how to (1) optimize clinical outcomes through earlier
use of fluocinolone acetonide (FAc) implant (ILUVIEN®) in patients with persistent or
recurrent DME despite therapy; and, (2) to provide guidance to assist physicians in deciding
which patients should be treated with ILUVIEN. In this regard, a 36-month follow-up
consensus protocol is presented. In conclusion, patients that achieve a complete or partial
anatomical, and preferably functional, response following one or two intravitreal dexametha-
sone implants, but with recurrence of edema after 3–4 months, are deemed by the authors
most likely to benefit from ILUVIEN, and the switch to FAc implant should not be delayed
more than 12 months after the initiation of at least the first dexamethasone implant.
Keywords: diabetic macular edema, DME, fluocinolone acetonide implant therapy,
ILUVIEN
Introduction
Anti-vascular endothelial growth factor (anti-VEGF) therapy, with or without
adjunctive focal laser treatment, has generally become the global standard of
care and used as a first-line therapy to improve visual outcomes in center-
involved diabetic macular edema (DME).1 Not all eyes that receive anti-VEGF
or laser photocoagulation show complete resolution of DME with improvement
of vision, however. Despite applying “pro re nata” (PRN) or “treat and extend”
(T&E) regimens, with a varying mean of 6–10 injections per year, approxi-
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have persistent edema, or both.2–4 Several factors may
contribute to suboptimal outcomes among DME patients
treated with anti-VEGF therapy, such as delays in diag-
nosis and/or treatment, insufficient response to therapy,5
and more definitively, the impossibility of physicians to
administer therapies according to the standard-of-care
(SoC) in real-life practice.6 Factors that have been exa-
cerbated by the current corona virus pandemic and also
led to patients fearing traveling to and attending clinical
appointments to receive therapy.
Following anti-VEGF treatment, the intravitreal dexa-
methasone implant OZURDEX®) and the fluocinolone
acetonide (FAc) intravitreal implant (ILUVIEN®) are com-
monly used as second-line treatments in DME, although
these therapies are increasingly being used earlier in the
treatment algorithm in Spain due to their high efficacy and
response rates, as well as their proven safety profile in
real-life.7 In some particular cases, dexamethasone
implants are even used as first-line therapy in naïve
patients with positive functional outcomes.8,9
A single dexamethasone implant has a short-term
action of up to 6 months,10,11 compared with up to 36
months of continuous treatment with the longer-acting FAc
implant.7,12 Further advantages of sustained intravitreal
release of the FAc implant include reduction in the fre-
quency of injections and clinic visits, with subsequent
lower rates of complications (such as retinal detachment,
endophthalmitis and lens iatrogenic injury) related to
injection procedure, higher patient compliance and lower
healthcare costs.13–15
Based on the authors’ real-life experiences managing
DME with the FAc implant in clinical practice, the current
approach to DME treatment is challenged. To better iden-
tify and select the DME patients who would benefit from
FAc implant, a consensus of the authors’ opinions was
reached following a meeting of retinal specialists held on
March 7th, 2019 in Madrid, Spain. The current review was
designed to provide a general introduction to DME as well





Diabetes is a group of inflammatory chronic metabolic
diseases characterized by elevated blood glucose and
degenerative damage to blood vessels.16,17 The
pathogenesis of microvascular complications is complex,
and involves metabolic and hemodynamic disturbances,
extending beyond hyperglycemia to include insulin resis-
tance, dyslipidemia, hypertension, and immune
dysfunction.18 These disturbances initiate several dama-
ging processes, such as increased reactive oxygen species
(ROS) production, inflammation, and ischemia.18
Diabetic retinopathy (DR) is a frequent inflammatory
and neurovascular complication of diabetes and the main
cause of irreversible vision loss in the working-age
population.19,20 A global meta-analysis study reported
that 35.4% of patients with diabetes had some form of
DR.21 It is also noted that 1 in 10 (11.7%) had potentially
vision-threatening retinal changes such as DME.21
DME is a Chronic, Inflammatory
and Recurrent Disease
DME is characterized by macula thickening due to accu-
mulation of exudative extracellular fluid derived from
hyperpermeable retinal capillaries in the macula.22 It is
the most common form of vision-threatening retinopathy
in people with diabetes, affecting approximately 7%
(range 4–18%) of patients with diabetes and more than
20 million individuals worldwide.22–26 Alteration of the
blood–retinal barrier, release of inflammatory mediators,
and ischemic processes are possible mechanisms for vision
loss due to DME.27
Inflammatory processes play an important role in DR
pathogenesis.28–30 In DME patients, levels of inflamma-
tory cytokines, VEGF, as well as the important modulator
of angiogenesis, angiopoietin-2, are significantly
elevated.31–33 However, the most compelling evidence
pointing to inflammation as a critical contributor to the
development of DR is the dramatic anti-inflammatory and
anti-edematous effect of corticosteroid treatment in
DME.34 Significant decreases in retinal thickness have
been observed within 1 hour of intravitreal triamcinolone
acetonide (IVTA) injection, though no change was seen
with bevacizumab after 24 hours.35 In addition, corticos-
teroids reduce edema and prevent angiogenesis, which
may be partly attributed to their ability to block VEGF
gene expression.36 Treatment with a long-term intravitreal
corticosteroid, which requires fewer injections than treat-
ment with short-acting therapies, has been found to reduce
inflammation and stabilize/improve vision in the majority
of patients.37–39 Continuous daily treatment, eg, as with
the FAc implant, may help to reduce under treatment for
Adán et al Dovepress
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36 months and, therefore, reduce the likelihood of edema
recurrence that is stated to drive long-term damage to the
retina due to the constant presence of intra and/or subret-
inal fluid accumulation, development of disorganization of
the retinal inner layers (DRIL), and poor long-term func-
tional outcomes.40,41
Consensus on DME Unmet Clinical
Needs
Despite the available treatment options for DME, there are
several unmet clinical needs that the FAc implant could
address if it was to be included in routine clinical practice.
Almost all the patients on dexamethasone intravitreal
implant treatment have recurrent edema <5 months after
an injection.13,42 Compared with FAc implants, dexa-
methasone implants have a short-term effect, resulting in
a see-saw pattern of intermittent improvement and regres-
sion in macular thickness.43–45
DME management with reactive regimens leads to peri-
ods of undertreatment. The decision to re-treat patients
involves “watching and waiting” for retinal signs or symp-
toms, which means frequent clinic visits periodically, based
on a set of prespecified criteria, as determined by the physi-
cian (eg, visual acuity (VA) and optical coherence tomogra-
phy (OCT)/fluorescein angiography assessments).46–48
There is a high treatment burden for patients with
diabetes, along with additional time required from any
accompanying carer6,49,50 There is also lack of
a treatment that could improve patients’ quality of life,
as well as family and healthcare system burden.51,52
Non-adherence to treatment and follow-up regimens
is a common problem in the management of patients
with DME and limits clinical treatment outcomes under
real-life conditions.49,53 In real life, there is lower
patient non-adherence to intravitreal treatment in DME
(44.0%) compared with other retinal diseases, such as
neovascular age-related macular degeneration (nAMD;
32.2%) or branch retinal vein occlusion (BRVO;
25.0%; p<0.01 between groups).49 Lower non-
adherence in DME patients is associated with a higher
risk of significant visual acuity loss.49
Anti-VEGF treatment in real life is not mirroring ran-
domized clinical trials (RCTs) as the treatment regimens
are impossible to follow, eg, in RCTs, a monthly injection
regimen was typically followed, resulting in a mean best-
corrected visual acuity (BCVA) gain of approximately 12
letters, while in real-life the mean BCVA gains are much
lower, such as +4.7 letters if a PRN regimen is
followed.2,6,54 Dexamethasone treatment is also difficult
to follow in real-life and requires more frequent reinjection
than in clinical trials.13,55,56 Although retreatment with
dexamethasone implant for DME is recommended after 6
months, the therapeutic effect in most eyes lasts approxi-
mately 4 months.57 Indeed, in real-life DME studies, the
mean number of dexamethasone injections administered in
12 months is typically more frequent than recommended
(ie, >2 injections per year).13,55,56
Comparison of Corticosteroids
Short-acting intravitreal corticosteroid injections have
a limited duration of action, which require frequent re-
treatment (eg, dexamethasone implant). Intravitreal sustained-
release implants (eg, FAc implant) have been developed to
prolong the effect of fluocinolone acetonide and to lessen the
need for repeated application.58 Overall, there is a progressive
and continuous improvement of the macula and visual out-
comes with the FAc implant, maintained over 36 months.59
A comparison of the available short- and long-acting intravi-
treal corticosteroids are shown in Table 1.
Corticosteroid efficacy is dependent on release kinetics
(eg, burst height of corticosteroid concentration in the
vitreous and duration of release), which varies between
different corticosteroid formulations (burst height is 1–20
ng/g for FAc vs >1,100 ng/g for dexamethasone and
10,000 ng/g for triamcinolone acetonide [TA]).59–61
Drugs with high burst heights, such as intravitreal TA
and the dexamethasone implant, show the greatest effect
during this initial burst, followed by exponential fall of
drug concentration.10 In contrast, the FAc implant, with
a low burst height and near-zero release kinetics, is better
able to maintain efficacy over time.59
Efficacy differences may be partially explained by
the fact that affinities for TA and FAc for human gluco-
corticoid receptor are higher than dexamethasone (dex-
amethasone [IC50 2.95 nM] > triamcinolone [IC50 0.27
nM] > FAc [IC50 0.19 nM]), which may explain the
higher clinical dose of dexamethasone versus FAc.62–65
In addition, the water solubility is lower and lipophilicity
is higher for FAc compared to dexamethasone and TA
which increases the availability of the drug so a much
lower pharmacokinetic (PK) dose of FAc is needed in the
implant than dexamethasone or TA.64,66-69 Hence higher
doses are required to produce an appropriate therapeutic
effect due to weaker binding affinity and lower lipophi-
licity of dexamethasone and shorter duration of action of
Dovepress Adán et al
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TA. The combination of high affinity to the glucocorti-
costeroid receptor and more efficient delivery mechan-
ism means that an effective, low dose of FAc can be
delivered to the retina for up to 36 months.7,12
Fluocinolone Implant Technology
and Pharmacokinetics
The FAc implant is an injectable, non-bioerodible, intravi-
treal insert designed to provide stable, long-term delivery
of FAc to the eye continuously every day for 36 months.70
It was specifically designed by ophthalmologists looking
for more effective and efficient ways to treat inflamma-
tion-driven ocular diseases safely and locally.71
In a human PK study (the FAMOUS study), FAc con-
centrations in plasma were below the lower limit of quan-
titation of the assay (100 pg/mL) at all time points from
Day 1 through Month 36.12 The fact that plasma levels of
FAc were below the detectable limit supports its localized
action at the site of injected eyes. Aqueous humor FAc
concentrations remained stable from Month 6 to Month 36
for subjects who were not retreated (see Figure 1).
Notably, there is no significant difference in FAc plasma
concentration following the initial dose and following
reinjection of a second dose after 12 months.70
Phase III FAc Implant Studies –
A Brief Overview
The FAc implant is indicated for the treatment of vision
impairment associated with chronic DME, considered
insufficiently responsive to available therapies.70 The
0.19 mg FAc implant (0.2 µg/day) is effective for the
treatment of DME. Evidence of effectiveness is shown in
the Fluocinolone Acetonide in Diabetic Macular Edema
(FAME) studies (FAME A and B). FAME studies A and
B were Phase III, multicenter RCTs designed to assess the
efficacy and safety of a single injection of the FAc implant
over a 3-year period versus the SoC (mainly laser photo-
coagulation; Table 2).72,73
The primary endpoints of both studies were VA gain of
≥15 letters at 24 months (patients were followed up to 36
months), which was met in both FAME A and B. At both
24 and 36 months, chronic DME patients receiving FAc
implants achieved greater improvements in VA compared
with the sham group (Figures 2 and 3). These VA results
from FAME at 36 months follow-up form the basis for the
approved license of the FAc implant in Europe. Figure 2
shows the results at Months 24 and 36 of the proportion of
chronic DME subjects with ≥15 letter improvement from
baseline BCVA.7 Figure 3 shows the 24 and 36-month
analyses for mean gains in BVCA from baseline for
chronic DME patients.
Sustained reduction in central foveal thickening (CFT)
in the FAc-treated group from as early as the first follow-
up visit (week 1) was maintained through to Month 36
(Figure 4).7
Raised intraocular pressure and cataract formation are
well-known side effects of intraocular corticosteroids.
During the course of the 3-year FAME trial, 80.0% of eyes
receiving the FAc implant (FAc 0.2 µg/day) required cataract
surgery.7 However, the overall visual benefit after cataract
surgery was similar to that in pseudophakic patients.74
Patients in the FAc implant group experienced more intrao-
cular pressure (IOP)-related adverse events overall than
patients in the sham group (FAc = 37.1% vs sham = 11.9%).7
Overall, there was a markedly better relative benefit for
patients with chronic DME compared with sham patients,
suggesting that patients with chronic DME who tend to
respond poorly to many treatments, including focal/grid
laser photocoagulation, respond well to administration of
the FAc implant.7
Real-World FAc Implant Studies
Patient populations in real-world studies typically have
more severe characteristics and are more heterogeneous
than those in RCTs. In the FAME trial, all patients had
received at least one prior focal/grid macular laser treat-
ment, although all FAME participants were treatment-
naïve for intravitreal injections.73 In the real-world setting,
Figure 1 FA levels in human aqueous humor in subjects receiving one ILUVIEN®
implant (FAMOUS Study).
Notes: Data from Campochiaro et al.12 FAc, 0.2 μg/day fluocinolone acetonide
(ILUVIEN).
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the FAc implant is chosen by clinical-decision for second-
or third-line treatment. In contrast to FAME, all chronic
DME patients in the real-world ILUVIEN Registry Safety
Study (IRISS) study had demonstrated insufficient
response to a wider range of prior DME therapies, mainly
intravitreal anti-VEGFs but also corticosteroids in some
cases. Furthermore, IOP was an exclusion criterion in the
FAME study, but 5.2% of patients in IRISS had an IOP
>21 mmHg at baseline.75
Table 2 compares FAME study results with key real-
world study results that demonstrate the efficacy and
safety of the FAc implant. Notably, the results from the
largest European (ie, IRISS, MEDISOFT Audit, and
Retro-IDEAL) studies represent the largest pool of real-
Figure 2 Percentage of subjects with ≥15 letter improvement from baseline in best corrected visual acuity (BCVA) at 24 and 36 months in patients with DME treated with
0.2 μg/day FAc implant versus sham injection.
Notes: Data from Campochiaro et al.7 , and ILUVIEN® Spanish Summary of Product Characteristics.70 *P = 0.002 FAc vs sham at Month 24; **P < 0.018 FAc vs sham at
Month 36; ***P < 0.001 FAc vs sham for both at Month 24 and 36. Full study population, N= 376 (FAc), N = 185 (sham); Chronic DME subgroup, N = 207 (FAc), N = 111
(sham).
Abbreviation: DME, diabetic macular edema; FAc, 0.2 μg fluocinolone acetonide (ILUVIEN).
Figure 3 Mean gains in best corrected visual acuity (BVCA) from baseline at 24 and 36 months in patients with chronic DME treated with 0.2 μg/day FAc implant.
Notes: *P = 0.35 vs sham at Month 24; **P = 0.04 vs sham at Month 36.; FAc, 0.2 μg fluocinolone acetonide.
Abbreviations: DME, diabetic macular edema; FAc, 0.2 μg fluocinolone acetonide (ILUVIEN®).
Adán et al Dovepress
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world data on the usage of the FAc implant in clinical
practice. The proportions of patients requiring IOP-
lowering incisional glaucoma surgery were lower in the
real-world studies compared with those observed in FAME
(IRISS = 0.8%, MEDISOFT Audit = 0.8% at 18 months
versus FAME at 18 months = 1.5%).7,38,39 IOP is main-
tained following FAc implant administration. After receiv-
ing one FAc implant, 86.1% of the patients did not require
any intervention to manage IOP after 24 months of follow-
up in the MEDISOFT Audit study.39 Other single-center
studies have followed patients for three years after
ILUVIEN therapy (Table 2) and report similar values
(mean=23.6%; range, 6.9% to 38.1%).
Clinical-Decision Criteria to Identify
Patients Suitable for ILUVIEN
Therapy
Efficacy results with the FAc implant were observed in
pharmacological-naïve patients in the Phase III RCT
(FAME), with a mean gain of +7.6 letters vs +1.8 letters for
the treated group compared with the sham group; of note,
34% of treated patients gained ≥15 letters at 36 months
compared with only 13.4% of patients in the sham group.7
RCTs are valuable in understanding the efficacy and
safety of the FAc implant; however, current real-world
studies include all patients with DME treated with the
FAc implant and provide a wider indication of the
implant’s effectiveness and safety. Table 2 summarizes
the largest real-world studies. It is notable that most
(99%) patients have received the FAc implant as second-
or third-line treatment in the Phase IV registry study,
IRISS.38 Irrespective of this, an improvement of 3.7 letters
(in all DME eyes) was recorded by Month 12 and similar
improvements (~5 letters) have been reported in other
studies (eg, MEDISOFT and Retro-IDEAL at 24 and 36
months) (Table 2) where patients have received the FAc
implant as a second- or third-line therapy and where long-
standing disease is evident. The IRISS study also sug-
gested that patients with short-standing chronic DME
may achieve better outcomes than those with long-
standing chronic DME and supports better outcomes for
patients when they are treated earlier in the disease (Table
2).38 The limitations of these studies have been reported,
but one important point is the limited number of patients
that have three years of follow-up which is needed to
confirm the effectiveness and safety of the FAc implant
in clinical practice. A number of smaller studies (see Table
2) have assessed effectiveness over three years and show
improvements in visual acuity ranging from 7.5 to 11.0
letters. These studies are also important in trying to under-
stand the effectiveness of the FAc implant in multi-ethnic
populations,76 following anti-VEGF therapy,77 following
a prior dexamethasone implant,77 in different regions
within the same country and in different countries.76–79
Figure 4 Mean central foveal thickness (CFT) change in patients with chronic DME treated with 0.2 μg/day FAc implant.
Notes: Data from Campochiaro et al.7, and ILUVIEN® Spanish Summary of Product Characteristics.70 *P = 0.005 vs sham at Month 24.
Abbreviation: DME, diabetic macular edema; FAc, 0.2 μg fluocinolone acetonide (ILUVIEN).
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Several investigators have concluded that, due to the
clear IOP-related safety and visual acuity benefits for short-
term DME patients, the FAc implant should be positioned
earlier in the DME treatment algorithm,38 ie, a DME patient
who has received one or two previous dexamethasone
implant injections, showing the presence of DME from
3–4 months following injection, should be considered for
switching to FAc implant. This would mean that this patient
has recurrent DME and will continue requiring injections for
a long period of time. Therefore, the dexamethasone implant
test-time should be no longer than 12 months to avoid
performing a high number of unnecessary injections of
a suboptimal treatment. In clinical practice, it is observed
that DME with a pattern of >2 edema recurrence events
during the first year is, expectantly, repetitive and replicated
during the second and third years.
Recommendation – Patients That May
Benefit from FAc Implant Therapy
In our opinion, the main patient profile that could benefit
from the FAc implant is for patients with a complete anato-
mical response after one injection of dexamethasone implant
for those patients whom the retina layers are preserved.
Regarding OCT biomarkers, there are signals which indicate
that edema is not recent, such as subretinal fluid, presence of
DRIL, disorganization/disruption of outer retinal layers and
the presence of hyperreflective foci. These signals indicate
a worse prognosis, irrespective of the chosen therapy. Indeed,
the FAc implant has shown efficacy even in those patients
that had insufficient response to previous therapies.38
It has also been previously stated that the FAc implant
could be an alternative option for those DME patients that
showed insufficient response to either anti-VEGF agents or
short-lasting corticosteroids.80,81 Owing to the insufficient
response to previous treatments in Phase IV studies, the FAc
implant could also be an option for patients that do not have
a complete anatomical response or vision improvement after
one injection of dexamethasone implant, as has been demon-
strated in real-world practices,82 because the FAc implant
contains a different molecule that could induce a different
response.
Protocol for the Management and
Monitoring of DME Patients Treated
with the FAc Implant
Based on the existing evidence on the effect of the FAc
implant, as well as on the clinical experience of a group of
medical and surgical retinal experts, a general protocol has
been established to monitor FAc implant treatment in
DME patients (see Table 3 and Figure 5). Further, pre-
FAc and post-FAc implant safety considerations, as well as
a post-injection algorithm when there is an IOP increase,
have been proposed by glaucoma specialist, Dr Marta
Pazos (see text below and Figure 6). These safety consid-
erations are based on the Hospital Clínic de Barcelona’s
glaucoma service experience of IOP events related to
intravitreal corticosteroids (triamcinolone, dexamethasone
implant and FAc implant) and on available medical
literature.
Safety Considerations
1. Ocular hypertension (OHT) and glaucoma are not the
same: Most of the time glaucoma will show as an
increased “cupping” of the optic disc with a peripapillary
nerve fiber layer thickness reduction by OCT, whereas
OHT will appear as a healthy-looking optic disc with
peripapillary RNFL thickness between normal limits.
Glaucoma is diagnosed based on the presence of
a characteristic optic neuropathy (focal or generalized
thinning of the neuroretinal rim with excavation and enlar-
gement of the optic cup) with a corresponding visual field
defect without regard of the level of IOP. Patients with
elevated IOP in the absence of optic nerve damage are
considered ocular hypertensives. It is known that between
30–50% of all subjects diagnosed with glaucoma do not
have high IOP at diagnosis.83
However, IOP has been shown to be the most impor-
tant risk factor for the disease, at all levels of pressure, all
ages, and all stages of the neuropathy.84–86
In recent years, spectral domain optical coherence
tomography (SD-OCT); especially peripapillary retinal
nerve layer (pRNFL)-analysis is playing an increasing
role in glaucoma diagnosis, discriminating very well
between healthy and glaucomatous eyes.87
2. OCT to rule out glaucoma: Perform a peripapillary
RNFL OCT at baseline; these should be repeated for an IOP
increase of >21mmHg, and suspected or diagnosed glaucoma,
particularly with a family history of glaucoma. Consider visual
field testing in high-risk patients or in cases of doubt.
3. Effect of corticosteroids on IOP: Corticosteroids
induce changes in the trabecular extracellular matrix,
which lead to decreased outflow facility. Elevated IOP
usually develops 2–6 weeks after initiating therapy, but
may occur at any time.88 Approximately 30% of healthy
patients are corticosteroid-responders, but these
Adán et al Dovepress
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percentages are different (11–79%), depending on several
factors, such as dosage, chemical structure, time duration,
administration route and individual susceptibility.89,90
There are several known risk factors that predispose to
corticosteroid-induced IOP elevation: primary open angle
glaucoma (with as much as 97% of patients responding),
family history of glaucoma, diabetes, myopia, rheumatoid
arthritis, uveitis, children, and elderly patients.89
4. Not all the corticosteroids are equal: Intravitreal dex-
amethasone is a free-floating biodegradable implant that
consists of dexamethasone embedded in a degradable poly-
mer, which results in a gradual release of medication for not
more than 6 months. In a real-world setting, the cumulative
probability of having an IOP ≥21 mmHg was 60% at 24
months after injection with intravitreal dexamethasone.95 At
24 months, 54% of the eyes required IOP-lowering topical
treatment in the real-world study (n = 353).95 Glaucoma
surgery was performed in 0.9% of eyes (4/429) in real-life.95
The FAc implant is a non-biodegradable intravitreal
implant of 0.19 mg of FAc that releases the medication at
a rate of 0.2 µg/day over 36 months. In the real-world IRISS,
the mean IOP in the entire cohort remained in the normal
range throughout the 24-month follow-up period, and the
majority of DME patients (76.7%) did not require IOP-
lowering therapy following treatment with the FAc
implant.38 In IRISS, 23.3% of patients required IOP-
lowering medication compared with 13.9% of patients in the
Medisoft audit also at 24-month follow-up.38,39 The low pro-
portion in the latter likely reflects clinical practice in the UK,
as all Medisoft sites were UK-based.39
If an IOP-related event is not experienced with
a previous dexamethasone implant, the risk that it will
occur with the FAc implant may be reduced. This conclusion
is based on a real-life study showing no adverse events in
a subgroup of DME patients where a prior corticosteroid had
been given and where there had been no prior IOP events.39
If there is an increase of IOP with short-acting intravitreal
corticosteroid injections, and if IOP required at least two
IOP-lowering medications to be under control, an increased
risk for IOP-lowering surgery should be anticipated; there-
fore, a close follow-up with a glaucoma specialist is strongly
recommended. This conclusion is based on a real-life study
by Pessoa et al. (2018),96 where, in a retrospective analysis,
all of the patients who needed surgery for OHT (3/28
patients; 11%) were on at least two IOP-lowering medica-
tions after short-acting intravitreal corticosteroid injection.92
5. Practical considerations to prevent/treat IOP eleva-
tion: if the increase in IOP during the pre-injection phase
(see top panels in Figure 6), consider including RNFL
OCT in the protocol for all patients at baseline and look
to identify high-risk patients by closely following-up the
patient.
Once the corticosteroid has been administered include
the following: (a) the IOP needs to be checked at every
appointment (every 3 months) and no extra tests are
needed if IOP <21 mmHg; (b) if IOP is between 22 and
25 mmHg in a healthy eye (normal nerve, normal OCT
RNFL), treatment is not needed, but check IOP and new
OCT RNFL at 6 weeks (consider performing visual field)
and if it is normal then control using standard follow-up
(including OCT RNFL every 6 months); (c) if IOP is >25
mmHg in a healthy eye (normal nerve, normal OCT
RNFL), start treatment with topical hypotensive drops
(ideally avoiding prostaglandin analogues if possible) and
perform an OCT RNFL and a visual field test. These
recommendations are based on the management of IOP
Table 3 General Pre- and Post-Injection Action Protocol for FAc
Implant Treatment
Medical Exam (Pre-injection)
● An OCT examination should be performed to detect signals of
ellipsoid zone integrity, hyperreflective dots, DRIL and intraretinal
or subretinal fluid, and to generate an image of what the patient’s
prognosis could be.
● Goldmann applanation tonometry and retinal nerve fiber layer
OCT analysis, as well as visual field examination (optional), should
be performed in order to obtain baseline information about the
IOP level, optic disc anatomy and cup-to-disc ratio. This baseline
information will be useful to compare with future follow-up
information.
● The use of the FAc implant in aphakic patients should be analyzed
according to the benefit–risk assessment because of the risk of
migrating the implant into the anterior chamber.
● Comment from the group of experts: Most physicians adhere to the
published summary of product characteristics (SmPC) showing that
glaucoma is considered a contraindication for the use of the FAc
implant.70
Follow-up checks for 36 months (post-injection)
● Check at one week post-injection to exclude any adverse effects
related to the intravitreal injection, and then follow the patient
every 3 months (eg, using information from the SmPC).70
● In the follow-up visits, the anatomical efficacy of the treatment
should be tested using OCT to look at central macular thickness
(CMT) and macular volume. The functional efficacy (ie, BCVA)
should be checked. Fundus and diabetic retinopathy status/pro-
gression should also be checked.
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as proposed by Goñi et al. (2016).93 Further, if IOP is still
high with two drugs or there are changes in the OCT
RNFL or visual field, refer the patient to a glaucoma
specialist. Finally, in eyes with controlled prior glaucoma,
individualize action protocol with a glaucoma specialist.
Supplemental Treatments Following
Treatment with the FAc Implant
Regarding additional treatments, the current literature
the largest datasets (Table 2) show that around 30% of
DME patients treated with the FAc implant need addi-
tional therapy.38,39,94 The IRISS study reported the
mean time to supplemental treatment was 356.1 ±
274.8 days and that the majority (22.4%) of eyes
received supplement anti-VEGF therapy.38 It is recom-
mended that if a recurrence of DME is detected at any
point during the follow-up, it is recommended to wait
and observe the patient for up to 6 months, depending
on the severity of the edema, to see if it has resolved.
If not, a combination therapy with anti-VEGF, laser
photocoagulation or an additional intravitreal injections
of corticosteroid should be considered, depending on
the previous response to each treatment.
Other real-world studies75–79 have reported 3-year
outcomes and it is estimated from Table 2, that roughly
48.2% (range, 30.0% to 83.3%) of patient eyes will
require supplemental treatments. On average, 7.9
(range, 5.0 to 13.1) treatments may be required with
a mean time to administrated being around 16.0
(range, 12.8 to 21.8) months.
Conclusions
There is a gap between clinical decisions based on real
medical needs and drug labeling or public health agency
requirements. Based on the authors’ real-life experiences
managing DME with the FAc implant in clinical prac-
tice, a consensus of clinical-decision criteria to help
physicians identify recurrent DME patients has been
proposed.
Overall, patients eligible for FAc implant treatment
should be identified as those DME patients that exhibit
an anatomical resolution of edema after one or two dex-
amethasone implants, but show edema recurrence, with
intraretinal and/or subretinal fluid after 3–4 months fol-
lowing the injection. It is agreed that the switch to the FAc
implant must be delayed no more than twelve months after
the start of the short-acting corticosteroid therapy. It is
consented that, during the treatment follow-up, OCT and
BCVA tests must be performed every 3 months. In addi-
tion, a safety protocol adapted to the long-lasting treatment
is proposed.
It is important to highlight that the current real-world
reactive treatment approach is not only influenced by physician
treatment decisions but also by hospital budgets for intravitreal
injections, ie, ophthalmology service saturation, as well as low
patient adherence to intravitreal treatment.
In the authors’ own clinical experience, it is observed
that DME with a pattern of >2 edema recurrence events
during the first year is repetitive and replicated during the
following years. Thus, as discussed above, many patients
could benefit from the FAc implant, a continuous daily
Figure 5 ILUVIEN® indication and follow-up pathway.
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Figure 6 Algorithm for the management of IOP elevation by retinal specialists: pre- (top panels) and post-corticosteroid injection (bottom panels).
Note: Adapted from Goni et al.93
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micro-dose treatment that controls DME for up to 36
months with a single injection.
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